Starting to think about what might be the specific candidates here. Of course Lilly is a major company in insulin but I am not sure that would be a target. Perhaps the oncology area where Lilly has products like
Cyramza which is a one hour infusion delivery. Anyone else have ideas?
thanks - sw
SAN DIEGO , Dec. 21, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.(HALO) today announced a global collaboration and license agreement with Eli Lilly and Company(LLY) to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE™ platform.
Under the terms of the agreement, Halozyme will receive an initial $25 million payment, followed by milestone payments of up to $160 million for each of up to five collaboration targets valued at up to $800 million. These payments are subject to Lilly's achievement of specified development, regulatory and sales-based milestones. In addition, Lilly will pay Halozyme mid-single digit royalties if products under the collaboration are commercialized
When does AMGN partner up?
Totally wrong. Satchfarm knows nothing. In fact the unethical government is prohibiting private debt collectors from certain practices, while the government is retaining the right to use those same practices in going after people who money to the government.
PRAA is one of the best and most compliant in this industry. The government under obama is non-compliant.
has to get the approval vote from shareholders. I have been getting lots of calls to vote my proxy, may be a sign that the approval is not a done deal...
sw - against the merger
It is also disgusting that the government is preventing certain modes of contact for the private debt collectors while continuing to use those same exact tactics to collect debts owed to the government.
PRAA has from the beginning been best in class in this business. There are bad actors and the latest FTC action is going after them. The current administration pays far too much attention to deadbeats. It is the E. Warren, approach which is totally wrong, hurting people who work hard and produce and rewarding those that do not.
People need to pay their bills. The current administration hates that idea for individuals or for the government as a whole. It prefers stealing.
This may be a case where the HALO is not allowed per the contract to discuss specifics. AbbVie brought iit up since Humira is very material and important to their financials.
See slide 17 of the most recent Investor Presentation. It has a line:
Delivery enhancements: Developing proprietary delivery technology (Halozyme) that may allow reduced
number of induction injections at higher doses, as well as other performance benefits.
By the way they see Humira sales over $18B by 2020.
that has not really been a problem in the large majority of cases with these thin ones. With ATRI I hardly have ever sold a share.